| Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition G Yu, GF Li, JS Markowitz Journal of child and adolescent psychopharmacology 26 (4), 314-326, 2016 | 100 | 2016 |
| Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling G Li, K Wang, R Chen, H Zhao, J Yang, Q Zheng Acta Pharmacologica Sinica 33 (11), 1359-1371, 2012 | 73 | 2012 |
| Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective G Yu, QS Zheng, GF Li The AAPS journal 16, 1162-1166, 2014 | 66 | 2014 |
| Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis GF Li, XX An, Y Yu, LR Jiao, D Canarutto, G Yu, G Wang, DN Wu, Y Xiao Gut 70 (9), 1806-1808, 2021 | 59 | 2021 |
| How to handle delayed or missed doses: a population pharmacokinetic perspective J Gu, Y Guo, Z Jiao, J Ding, GF Li European journal of drug metabolism and pharmacokinetics 45 (2), 163-172, 2020 | 27 | 2020 |
| Ethnic-specific in vitro–in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese … GF Li, G Yu, HX Liu, QS Zheng Clinical pharmacokinetics 53, 197-202, 2014 | 24 | 2014 |
| Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye G Yu, QS Zheng, DX Wang, HH Zhou, GF Li The Lancet Oncology 15 (11), e469-e470, 2014 | 22 | 2014 |
| Quantitative estimation of plasma free drug fraction in patients with varying degrees of hepatic impairment: a methodological evaluation GF Li, G Yu, Y Li, Y Zheng, QS Zheng, H Derendorf Journal of Pharmaceutical Science 107 (7), 1948-1956, 2018 | 20 | 2018 |
| Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and cytochrome P450 (CYP) 1A2 content on physiologically based prediction of CYP1A2-mediated … GF Li, QS Zheng, Y Yu, W Zhong, HH Zhou, F Qiu, G Wang, G Yu, ... Clinical pharmacokinetics 58, 927-941, 2019 | 17 | 2019 |
| Metabolic characteristics of Tanshinone I in Human Liver Microsomes and S9 Subcellular Fractions Y Li, Y Fan, H Su, Q Wang, GF Li, Y Hu, J Jiang, B Tan, F Qiu Xenobiotica, doi:10.1080/00498254.2018.1432087, 2018 | 12 | 2018 |
| Modeling Drug Disposition and Drug-Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective GF Li, QS Zheng Eur J Drug Metab Pharmacokinet 43 (3), 369-371, 2018 | 11 | 2018 |
| Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese G Yu, HH Zhou, QS Zheng, GF Li European journal of clinical pharmacology 75, 543-551, 2019 | 8 | 2019 |
| Gastric-acid-mediated drug–drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies G Yu, Y Zheng, Y Yu, GF Li, H Derendorf Drug Discovery Today 24 (3), 845-857, 2019 | 7 | 2019 |
| Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing G Yu, DN Wu, Y Yu, GF Li, HH Zhou Journal of Oncology Pharmacy Practice, doi: 10.1177/1078155217752535, 2018 | 7 | 2018 |
| Pooled analysis of gastric emptying in patients with obesity: implications for oral absorption projection CX Lu, XX An, Y Yu, LR Jiao, D Canarutto, GF Li, G Yu Clinical Therapeutics 43 (10), 1768-1788, 2021 | 6 | 2021 |
| Fasting conditions in clinical oncology trials and drug labelling G Yu, GF Li, DX Wang, J Wang, HH Zhou The Lancet Oncology 18 (9), e506. doi: 10.1016/S1470-2045(17)30585-5, 2017 | 6 | 2017 |
| Model-informed approaches for alternative aripiprazole dosing regimens and missed dose management: towards better adherence to antipsychotic pharmacotherapy JY Wu, G Yu, GF Li European Journal of Drug Metabolism and Pharmacokinetics 43, 471-473, 2018 | 5 | 2018 |
| Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? G Yu, DN Wu, Y Gong, GF Li, HH Zhou European Journal of Clinical Pharmacology, doi:10.1007/s00228-018-2439-z, 2018 | 5 | 2018 |
| Comment on:“a physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating … GF Li, X Gu, G Yu, SY Zhao, QS Zheng Clinical Pharmacokinetics 55 (1), 133-137, 2016 | 5 | 2016 |
| The role of a meal on gastrointestinal toxicity and maximum tolerated dose G Yu, DX Wang, GF Li, HH Zhou The Lancet Oncology 17 (1), e2-3. doi: 10.1016/S1470-2045(15)00552-5, 2016 | 5 | 2016 |
Hartmut DerendorfDistinguished Professor of Pharmaceutics, University of Florida在 ufl.edu 的电子邮件经过验证
